Diphlorethohydroxycarmalol isolated from <i>Ishige okamurae</i> improves age-related muscle dysfunction by Ca<sup>2+</sup>-dependent response <i>via</i> the SirT1/PGC-1α pathway <i>in vitro</i> and <i>i

Diphlorethohydroxycarmalol (DPHC) is a natural polyphenolic compound extracted from the brown seaweed Ishige okamurae. This study tested whether DPHC could counteract age-related muscle deterioration — a condition called sarcopenia — using both cultured muscle cells and zebrafish artificially aged with D-galactose. In cell culture, DPHC reduced markers of cellular aging, cut harmful reactive oxygen species, restored energy (ATP) production, and boosted calcium signaling. In zebrafish, it improved swimming performance, preserved muscle tissue architecture, and raised muscle ATP levels. The researchers traced these benefits to a specific molecular chain: DPHC raises intracellular calcium, which activates the enzyme CaMKKβ, which in turn switches on AMPK, ultimately upregulating the longevity proteins SirT1 and PGC-1α — a pathway central to mitochondrial health and muscle metabolism. The findings position DPHC as a candidate dietary or nutraceutical agent for age-related muscle decline, though the work is still at the preclinical stage.

• In D-galactose (200 mM)-treated C2C12 myoblasts, DPHC treatment significantly increased cell viability and reduced senescence-associated β-galactosidase (SA-β-gal) activity, a standard marker of cellular aging.
• DPHC elevated intracellular Ca²⁺ levels, suppressed ROS accumulation, and restored ATP production in aged C2C12 cells in vitro.
• In zebrafish exposed to 1% D-galactose for 6 weeks, DPHC administration improved swimming ability, preserved skeletal muscle integrity, reduced glycogen accumulation, and increased muscle ATP levels.
• Mechanistically, DPHC activated CaMKKβ and promoted AMPK phosphorylation in skeletal muscle, leading to upregulation of SirT1 and PGC-1α protein expression, linking Ca²⁺ signaling to the mitochondrial biogenesis axis.

The study used a dual-model approach: an in vitro model of cellular aging in C2C12 mouse myoblasts induced by 200 mM D-galactose, and an in vivo model of accelerated aging in adult zebrafish exposed to 1% D-galactose for 6 weeks. DPHC was administered to both systems at doses not specified in the abstract, and outcomes assessed included cell viability, SA-β-gal activity, intracellular Ca²⁺, ROS, ATP, swimming behavior, muscle histology, glycogen content, and protein expression of CaMKKβ, p-AMPK, SirT1, and PGC-1α. No mammalian in vivo model or human data were included in this study.

The in vivo component relies on zebrafish, which share key metabolic pathways with mammals but differ substantially in muscle physiology, metabolism, and translational relevance to human sarcopenia, limiting direct clinical extrapolation. D-galactose-induced aging is a chemical model that accelerates oxidative stress but may not fully recapitulate the multifactorial biology of natural aging in humans. Dose–response relationships and pharmacokinetic data for DPHC in mammals are not established, and it is unclear whether oral bioavailability of DPHC would be sufficient to reach skeletal muscle at effective concentrations. A next critical experiment would be replication in an aged rodent model (e.g., naturally aged mice) with pharmacokinetic profiling and assessment of off-target effects.

This study extends [§116], which examines age-related mitochondrial metabolic dysfunction through ALDH2 deficiency, by offering a complementary intervention angle — demonstrating that a natural compound can restore mitochondrial energy output (ATP) and reduce oxidative stress in aging muscle via Ca²⁺/CaMKKβ/AMPK/SirT1-PGC-1α signaling rather than aldehyde metabolism. It parallels [§99], which investigates mitochondrial RNA release as a driver of aging-associated inflammation and senescence, since both studies converge on the idea that upstream mitochondrial perturbations accelerate muscle and tissue aging, albeit through distinct molecular triggers. The Ca²⁺-dependent activation of AMPK and subsequent PGC-1α upregulation reported here also parallels work in [§134], where BMAL1 deficiency in cardiomyocytes disrupts mitochondrial quality control through PINK1/Parkin-linked mitophagy, underscoring that Ca²⁺ and energy-sensing pathways are recurrent nodes across different models of age- or metabolic-stress-driven mitochondrial dysfunction. Together these articles suggest the SirT1/PGC-1α axis is a convergence point for multiple upstream stress signals in aging tissues.

• Impact of aldehyde dehydrogenase 2 deficiency on tissue-specific mitochondrial metabolism in aging mice
  Both study age-related mitochondrial dysfunction in muscle tissue but through different molecular entry points — DPHC via Ca²⁺/SirT1 signaling versus ALDH2 deficiency via aldehyde metabolism — making direct mechanistic comparison informative.
• Mitigating Mitochondrial RNA Release During Aging to Control Inflammation and Senescence
  Parallels this article in framing aging-associated cellular senescence and mitochondrial decline as targetable, but focuses on mitochondrial RNA-mediated inflammation rather than Ca²⁺-dependent biogenesis, offering a contrasting upstream mechanism.
• Cardiomyocyte BMAL1 deficiency worsens obesity-related cardiomyopathy with heightened PINK1/Parkin-linked mitophagy and mitochondrial dysfunction
  Both articles implicate Ca²⁺ and energy-sensing (AMPK/SirT1/PGC-1α) pathways in mitochondrial dysfunction associated with metabolic or age-related stress, but in cardiomyocytes versus skeletal muscle, enabling cross-tissue comparison of shared signaling nodes.
• Exercise hormone irisin alleviates rheumatoid arthritis by removing dysfunctional mitochondria
  Irisin and DPHC both target dysfunctional mitochondria in musculoskeletal contexts (rheumatoid arthritis vs. sarcopenia), making this a useful comparison of exercise-mimetic versus dietary-phytochemical strategies for mitochondrial rescue.